Biosimilars are eating Humira's lunch

добавлена новая статья Sağlıklı Yaşam

2026-04-16 09:47:38 -

Humira (adalimumab) was a $20 billion drug — until biosimilars arrived in 2023. Now, prices have dropped by 50‑80%, making TNF inhibitors accessible to millions more patients. The TNF alpha inhibitors market forecast predicts that biosimilars will capture over 70% of the market by 2035. Why the shift? Because payers are forcing substitution, and patients are willing to...

0 Комментарии 0 Поделились 32 Просмотры 0 предпросмотр